Blinatumomab for Treatment of R/R or MRD-positive CD19-Positive MPAL

Clinical trial NCT04827745 · COMPLETED

Trial details

NCT number: NCT04827745
Sponsor: University of Maryland, Baltimore
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Mixed Phenotype Acute Leukemia (MPAL)Measurable Residual Disease (MRD)

Start date: 2021-06-11
Primary completion: 2025-05-22
Enrollment: 2

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.